HUI-GENE THERAPEUTICS
Hui-Gene is focused on R&D for single-gene disorders and has developed pilot pipes in neurodegenerative diseases.
HUI-GENE THERAPEUTICS
Industry:
Biopharma Biotechnology Genetics Life Science Medical Medical Device Pharmaceutical Therapeutics
Founded:
2018-10-01
Address:
Shanghai, Shanghai, China
Country:
China
Website Url:
http://www.huidagene.com
Total Employee:
11+
Status:
Active
Contact:
15221536625
Email Addresses:
[email protected]
Total Funding:
14.21 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Mobile Non Scaleable Content Nginx Euro Microsoft Azure DNS Apple Mobile Web App Capable Pound Sterling
Similar Organizations
Cerevance
Cerevance is a developer of novel therapeutics intended to advance new medicines for serious neurological diseases.
GigaGen
GigaGen specialized in the early discovery and development of recombinant biotherapeutic medicines.
Nurix Therapeutics
Nurix Therapeutics is a biopharmaceutical company that focuses on the development and discovery of small molecule drugs.
Vigil Neuroscience
Vigil Neuroscience is a biotechnology company that develops novel therapeutics for neurodegenerative diseases.
Current Employees Featured
Founder
Investors List
CD Capital
CD Capital investment in Series C - Hui-Gene Therapeutics
Kunlun Capital
Kunlun Capital investment in Series C - Hui-Gene Therapeutics
Sherpa Venture Capital
Sherpa Venture Capital investment in Series C - Hui-Gene Therapeutics
Mayo Clinic Ventures
Mayo Clinic Ventures investment in Series A - Hui-Gene Therapeutics
WuXi AppTec
WuXi AppTec investment in Series A - Hui-Gene Therapeutics
Hillhouse Capital Group
Hillhouse Capital Group investment in Series A - Hui-Gene Therapeutics
Huimei Capital
Huimei Capital investment in Series A - Hui-Gene Therapeutics
Sherpa Venture Capital
Sherpa Venture Capital investment in Series A - Hui-Gene Therapeutics
CD Capital
CD Capital investment in Series A - Hui-Gene Therapeutics
Official Site Inspections
http://www.huidagene.com
- Host name: 121.199.175.15
- IP address: 121.199.175.15
- Location: Hangzhou China
- Latitude: 30.294
- Longitude: 120.1619
- Timezone: Asia/Shanghai
More informations about "Hui-Gene Therapeutics"
辉大基因-HUIDAGENE
辉大基因是一家全球性的临床阶段生物技术公司，专注于设计、改造及开发新型crispr基因编辑工具和颠覆性的创新基因疗法。总部位于中国上海，并在美国新泽西设有办公室，辉大基因目标是 …See details»
About us-HUIDAGENE
About Us HuidaGene is a global clinical-stage biotechnology company focusing on discovering, engineering, and developing gene editing tools and gene therapies to rewrite the future of genomic medicine. Based in Shanghai and …See details»
FDA Clears HG202 CRISPR Therapy for Wet AMD Trials | OBN
Nov 6, 2024 In September 2023, HuidaGene dosed the world’s first patient with a CRISPR/Cas13 RNA-editing therapy, marking a critical advancement in gene therapy for …See details»
HuidaGene Therapeutics Co., Ltd. - Drug pipelines, …
HuidaGene is committed to transforming the future of genome-editing medicine. For more information, please visit or follow us on LinkedIn at ... The statistics for drugs in the Pipeline is the current organization and its subsidiaries are …See details»
HuidaGene Therapeutics - Crunchbase Company Profile & Funding
Organization. HuidaGene Therapeutics . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. About. ... HuidaGene utilizes its proprietary …See details»
Leadership-HUIDAGENE
Your privacy is very important to us. When you visit our website, please agree to the use of all cookies. For more information about personal data processing, please ...See details»
FDA Grants First Clearance for CRISPR/Cas13 RNA-Editing Therapy …
Nov 6, 2024 HuidaGene’s CRISPR Innovations HuidaGene has developed its RNA-editing technology through its AI/ML-driven HG-PRECISE® platform. Co-Founder Dr. Hui Yang …See details»
HuidaGene Therapeutics Receives the First-Ever FDA Clearance of …
Nov 4, 2024 Xin Zhang, M.D., MSc., COO and CMO of HuidaGene, highlighted the urgency of new nAMD treatments: "Up to 46% of AMD patients respond poorly or develop resistance to …See details»
HuidaGene Therapeutics - LinkedIn
HuidaGene Therapeutics team is meeting with partners, collaborators, and investors at #BIOEurope Fall organized by EBD Group and Biotechnology Innovation Organization to …See details»
Company: HuidaGene Therapeutics - CRISPR Medicine
HuidaGene is a global clinical-stage biotechnology company focusing on discovering, engineering, and developing gene-editing tools and gene therapies develop novel genetic …See details»
更名声明 | 辉大基因英文名称正式变更为HuidaGene Therapeutics
Feb 14, 2023 辉大（上海）生物科技有限公司（简称“辉大基因”）宣布，自2023年1月28日起，公司英文名称从原来的“HuiGene Therapeutics Co., Ltd.”正式变更为“HuidaGene Therapeutics …See details»
HUIADGENE ANNOUNCES RARE PEDIATRIC DRUG DESIGNATION …
Dec 19, 2023 SHANGHAI and CLINTON, N.J., Dec. 19, 2023 /PRNewswire/ -- HuidaGene Therapeutics (辉大基因"HuidaGene") today announced the U.S. FDA granted Rare Pediatric …See details»
HuidaGene Therapeutics - Funding, Financials, Valuation & Investors
How much funding has this organization raised over time? Show . Announced Date . Transaction Name . Number of Investors . Money Raised . Lead Investors . May 12, 2022: Series C - …See details»
Develop a Compact RNA Base Editor by Fusing ADAR with …
A .gov website belongs to an official government organization in the United States . Secure .gov websites use HTTPS ... IP & Legal Director from HuidaGene Therapeutics Co., Ltd., for kindly …See details»
HUIDAGENE THERAPEUTICS ANNOUNCES FIRST PATIENT DOSED …
Nov 1, 2023 SHANGHAI and CLINTON, N.J., Nov. 1, 2023 /PRNewswire/ -- HuidaGene Therapeutics (辉大基因，"HuidaGene"), a global clinical-stage biotechnology company …See details»
HuidaGene Therapeutics Receives the First-Ever FDA ... - Morningstar
Nov 4, 2024 HuidaGene Therapeutics Receives the First-Ever FDA Clearance of CRISPR/Cas13 RNA-Editing HG202 for Macular Degeneration. PR Newswire. SHANGHAI …See details»
HuidaGene’s LCA2 Gene Therapy Gets Orphan Drug Designation
Apr 3, 2023 The FDA previously cleared HuidaGene’s investigational new drug application (IND) in January 2023 and the first patient was treated with a single intravitreal injection oflow-dose …See details»
HUIDAGENE ANNOUNCES IND APPROVAL OF THE FIRST CHINA …
Apr 18, 2023 SHANGHAI and CLINTON, N.J., April 18, 2023 /PRNewswire/ -- HuidaGene Therapeutics (辉大基因; HuidaGene), a clinical-stage biotechnology company developing …See details»
HuidaGene Receives Orphan Drug Designation for Gene Therapy …
Apr 3, 2023 The percentage of patients (with biallelic RPE65 mutations) meeting the World Health Organization (WHO) criteria for blindness increased with age and reached 100% after …See details»